It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary

Clinical Trial Title: 
A prospective observational trial evaluating outcomes of FoundationOne: Directed matched targeted therapy in patients with cancer of unknown primary (CUP).
Clinical Trial Protocol ID: 
15071708
Clinical Trial Investigator Name: 
Marisa E. Hill, MD
Clinical Trial Protocol Description: 

The goal of the current study is to determine whether Foundation Medicine's next generation sequencing assay, called FoundationOne, will provide information that allows physicians to make treatment decisions using targeted therapies in clinical trials or FDA approved therapies, including "off-label" agents, that result in superior OS compared to historical outcomes for standard CUP therapy.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have a histologically or cytologically confirmed diagnosis of metastatic or advanced unresectable cancer of unknown primary including adenocarcinoma, poorly differentiated adenocarcinoma, poorly differentiated carcinoma, or squamous carcinoma.
  • Have measurable disease.
  • Are a first or second line patient with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2. Or, are a third line patient with an ECOG performance status score of 0 to 1.

Patients are considered potential candidates for treatment with targeted therapy.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-5526
Contact Name: 
Pam Sroka, BS, MT(ASCP), BSN, RN, CCRC